Defining the clinically appropriate prescription of medical cannabis
CPASS want to take advantage of the upcoming General Election on December 12th 2019 to raise awareness of the continuing plight of medical cannabis patients in the UK
a more detailed analysis of the NHS England and NHS Improvement’s report on the Barriers to accessing cannabis-based products for medicinal use on NHS prescription
There is a great deal to say about 2 recent publications; NHS Barriers to Prescribing Review and NICE Guideline for CBMPs, and whilst there are areas for optimism, in the most part, both illustrate that we are not making anywhere near the kind of progress that patients should be able to expect from our “world-class” medicines approval and healthcare systems. When you consider the progress being made in other jurisdictions, “world-class” is not something the UK will be able to boast for much longer unless there are significant changes made across the board.
The 40th meeting of the Expert Committee on Drug Dependence (ECDD) was a specially convened session dedicated to carrying out pre-reviews of cannabis and cannabis-related substances and was held in Geneva, Switzerland, 4-7 June 2018. The 41st meeting will be in November 2018
The 2018 Medical Cannabis Survey of over 1750 medical cannabis patients was the first of its kind in the UK.